Wolfgang Knirsch
Vita 34 AG, Germany
Biography
Wolfgang Knirsch has been a member of the board of Vita 34 AG since June 2016 and was appointed CEO of Vita 34 AG in June 2017. After he received his Ph.D. in inorganic chemistry from RWTH Aachen he holds leading positions in the ï¬ eld of marketing & sales at Hoechst AG, Merk KGaA and Biotest AG. He also was also in charge of the product management of internationally relevant ethical preparations of the successor company Aventis Pharma GmbH. In the position of Vice President of International Business, he successfully advanced the strategically relevant department worth several hundred million Euros involving distribution partners worldwide.
Abstract
Abstract : Limiting factors to the therapeutic use of CBUs and how to overcome them